Multidrug resistance (MDR) is the main cause of chemotherapy failure in the treatment of colon cancer and the high expression of drug efflux protein P-gp is one of the main factors of MDR. P-gp expression is regulated by the signal transducer and activator of transcription 3 (STAT3) signaling pathway. In this study, human colon cancer oxaliplatin-resistant cells were treated with oxaliplatin combined with the natural product erianin. Then, we evaluated the impact of erianin on drug resistance, and explored the relationship between erianin-related oxaliplatin resistance and the Janus kinase 2/STAT3 signaling pathway in vitro. Our research showed that erianin could significantly inhibit the proliferation of human colon cancer oxaliplatin-resistant cells, and suppress the cell cycle of oxaliplatin-resistant cells in the G2/M phase, indicating that erianin could regulate the MDR phenotype of oxaliplatin-resistant cells, and its mechanism might be the inhibition of STAT3 signaling pathway and the significant reduction of P-gp expression. However, this study provides a theoretical basis for the clinical application of erianin in platinum-based chemotherapy for colon cancer.

中文翻译：

---

毛兰素逆转人结肠癌细胞奥沙利铂耐药的作用及机制

多药耐药(MDR)是结肠癌治疗中化疗失败的主要原因，药物外排蛋白P-gp的高表达是导致MDR的主要因素之一。P-gp 表达受信号转导和转录激活因子 3 (STAT3) 信号通路的调节。在这项研究中，人结肠癌奥沙利铂耐药细胞采用奥沙利铂联合天然产物毛兰素进行治疗。然后，我们评估了毛兰素对耐药性的影响，并在体外探讨了毛兰素相关的奥沙利铂耐药与 Janus 激酶 2/STAT3 信号通路之间的关系。我们的研究表明，毛兰素能显着抑制人结肠癌奥沙利铂耐药细胞的增殖，抑制奥沙利铂耐药细胞在G2/M期的细胞周期，说明毛兰素可以调节奥沙利铂耐药细胞的MDR表型，其机制可能是抑制STAT3信号通路，显着降低P-gp表达。但本研究为毛兰素在结肠癌铂类化疗中的临床应用提供了理论依据。